Document Detail


Weight gain associated with valproate in childhood.
MedLine Citation:
PMID:  10913727     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Weight gain is a common side effect of valproate treatment. Several mechanisms have been suggested for its pathophysiology; of these, impairment of beta-oxidation of fatty acids and increased insulin secretion have been supported by clinical studies. To investigate whether changes in carnitine and insulin levels had a role in the weight gain occurring with valproate treatment in children, 20 patients with epilepsy were randomly assigned to receive either carnitine or placebo supplementation in addition to valproate. After a follow-up period of 3 months, weight gain was observed in both groups. The mean insulin concentration and insulin/glucose ratios increased. Weight gain did not correlate with carnitine levels. These results suggest that weight gain during valproate treatment is not related to a decrease in carnitine levels. However, an increase in insulin levels together with a decrease in glucose levels may cause weight gain, possibly by stimulating appetite.
Authors:
E Demir; S Aysun
Related Documents :
20123087 - Metformin induces suppression of nad(p)h oxidase activity in podocytes.
11315837 - Additive glucose-lowering effects of glucagon-like peptide-1 and metformin in type 2 di...
11220287 - Promising new approaches.
10206447 - Metformin-induced resumption of normal menses in 39 of 43 (91%) previously amenorrheic ...
20123087 - Metformin induces suppression of nad(p)h oxidase activity in podocytes.
16776887 - Racial disparities in diabetes-related preventive care: results from the missouri behav...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Pediatric neurology     Volume:  22     ISSN:  0887-8994     ISO Abbreviation:  Pediatr. Neurol.     Publication Date:  2000 May 
Date Detail:
Created Date:  2000-08-23     Completed Date:  2000-08-23     Revised Date:  2006-05-23    
Medline Journal Info:
Nlm Unique ID:  8508183     Medline TA:  Pediatr Neurol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  361-4     Citation Subset:  IM    
Affiliation:
Department of Pediatric Neurology, Hacettepe University, Ankara, Turkey.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Anticonvulsants / adverse effects*,  therapeutic use
Blood Glucose / drug effects
Carnitine / blood,  therapeutic use*
Child
Child, Preschool
Drug Therapy, Combination
Epilepsy, Generalized / blood,  complications,  drug therapy*
Female
Humans
Insulin / blood,  metabolism
Male
Treatment Outcome
Valproic Acid / adverse effects*,  therapeutic use
Weight Gain / drug effects*
Chemical
Reg. No./Substance:
0/Anticonvulsants; 0/Blood Glucose; 11061-68-0/Insulin; 541-15-1/Carnitine; 99-66-1/Valproic Acid

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Growth hormone deficiency in children with neurofibromatosis type 1 without suprasellar lesions.
Next Document:  Cerebral oxygenation state in childhood moyamoya disease: a near-infrared spectroscopy study.